New & different non-pharmacological mechanism of action

Vibrant is indicated for the treatment of adults with chronic idiopathic constipation who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month.

Significant improvement in incremental CSBMs

No severe adverse events. 1.2% diarrhea

Non-pharmacological

Circadian Rhythm & Constipation

Research shows that when the circadian rhythm is out of sync, it may lead to constipation1,2.

Vibrant has a different mechanism of action – using gentle vibrations to stimulate the colon mechanically.

The pre-programmed timing of the mechanical stimulation is thought to improve the natural colonic motility by leveraging the colon’s biological clock.

Clinical research demonstrates an increased number and frequency of complete bowel movements and improvement in the quality of life, with 1.2% diarrhea occurrence.

Vibrant developed a new non-pharmaceutical mechanism of action based on intraluminal mechanical stimulation

1. Activate

The patient places the capsule in the pod for an automatic activation

2. Ingest

The patient swallows the capsule with a glass of water

3. Constipation relief

Intraluminal mechanical stimulation improves natural motility

Vibrant results statistically significant and clinically meaningful

6 multi-center clinical studies completed

137 clinical sites primarily in the US

850 chronic constipation patients

Efficacy and Safety of the Non-Pharmacological Vibrant® System for Chronic Idiopathic Constipation (CIC):

Randomized, double-blind, multicenter, placebo-controlled, phase 3 trial

Rao SSC, Quigley EMM, Chey WD, Sharma A, Dinh D., Dunn L., Fogel R., Romero S., Teltser M. ,Morin P., Torres L., Surowitz R., Reddy V. , Wayne J., Beaulieu E., Snook M., Goldstein G., Rubino J., Freeman G., Lumicao B., Greenwald J., Shah S., Zopo A., Wild J., Hellstern P., Murray A., Usdan L., Goldstein G., Whitmer D., Oza A., Friedenberg K., Lembo A, et al

Conclusions

Vibrant significantly improved stool frequency, other bowel and abdominal symptoms and quality of life in patients with CIC. These benefits were seen soon after the initiation of therapy and were sustained with no significant adverse events.


Vibrant provides a novel, non-pharmacological, intraluminal therapy which is efficacious, safe and well tolerated in patients with CIC.

What do your colleagues think about the phase 3 results?

Whom to prescribe?

Vibrant is indicated for the treatment of adults with chronic idiopathic constipation who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month.

I want to be trained on Vibrant